Gelardi, F.; Tiberio, P.; Torrisi, R.; Zanca, R.; Rodari, M.; Zambelli, A.; Santoro, A.; Fernandes, B.; Sagona, A.; Errico, V.;
et al. Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort. Cancers 2025, 17, 2133.
https://doi.org/10.3390/cancers17132133
AMA Style
Gelardi F, Tiberio P, Torrisi R, Zanca R, Rodari M, Zambelli A, Santoro A, Fernandes B, Sagona A, Errico V,
et al. Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort. Cancers. 2025; 17(13):2133.
https://doi.org/10.3390/cancers17132133
Chicago/Turabian Style
Gelardi, Fabrizia, Paola Tiberio, Rosalba Torrisi, Roberta Zanca, Marcello Rodari, Alberto Zambelli, Armando Santoro, Bethania Fernandes, Andrea Sagona, Valentina Errico,
and et al. 2025. "Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort" Cancers 17, no. 13: 2133.
https://doi.org/10.3390/cancers17132133
APA Style
Gelardi, F., Tiberio, P., Torrisi, R., Zanca, R., Rodari, M., Zambelli, A., Santoro, A., Fernandes, B., Sagona, A., Errico, V., Testori, A., Tinterri, C., Chiti, A., De Sanctis, R., Sollini, M., & Antunovic, L.
(2025). Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort. Cancers, 17(13), 2133.
https://doi.org/10.3390/cancers17132133